Targeted delivery of silibinin via magnetic niosomal nanoparticles: potential application in treatment of colon cancer cells

Golchin Shafiei; Davoud Jafari-Gharabaghlou; Mahdi Farhoudi-Sefidan-Jadid; Effat Alizadeh; Marziyeh Fathi; Nosratollah Zarghami

doi:10.3389/fphar.2023.1174120

Targeted delivery of silibinin via magnetic niosomal nanoparticles: potential application in treatment of colon cancer cells

Front Pharmacol. 2023 Jun 27:14:1174120. doi: 10.3389/fphar.2023.1174120. eCollection 2023.

Authors

Golchin Shafiei^{1

2}, Davoud Jafari-Gharabaghlou³, Mahdi Farhoudi-Sefidan-Jadid³, Effat Alizadeh¹, Marziyeh Fathi², Nosratollah Zarghami^{3

4}

Affiliations

¹ Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
² Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
³ Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
⁴ Department of Medical Biochemistry, Faculty of Medicine, Istanbul Aydin University, Istanbul, Turkey.

Abstract

Introduction: In recent years, various nanoparticles (NPs) have been discovered and synthesized for the targeted therapy of cancer cells. Targeted delivery increases the local concentration of therapeutics and minimizes side effects. Therefore, NPs-mediated targeted drug delivery systems have become a promising approach for the treatment of various cancers. As a result, in the current study, we aimed to design silibinin-loaded magnetic niosomes nanoparticles (MNNPs) and investigate their cytotoxicity property in colorectal cancer cell treatment. Methods: MNPs ferrofluids were prepared and encapsulated into niosomes (NIOs) by the thin film hydration method. Afterward, the morphology, size, and chemical structure of the synthesized MNNPs were evaluated using the TEM, DLS, and FT-IR techniques, respectively. Results and Discussion: The distribution number of MNNPs was obtained at about 50 nm and 70 nm with a surface charge of -19.0 mV by TEM and DLS analysis, respectively. Silibinin loading efficiency in NIOs was about 90%, and the drug release pattern showed a controlled release with a maximum amount of about 49% and 70%, within 4 h in pH = 7.4 and pH = 5.8, respectively. To investigate the cytotoxicity effect, HT-29 cells were treated with the various concentration of the drugs for 24 and 48 h and evaluated by the MTT as well as flow cytometry assays. Obtained results demonstrated promoted cell cytotoxicity of silibinin-loaded MNNPs (5-fold decrease in cell viability) compared to pure silibinin (3-fold decrease in cell viability) while had no significant cytotoxic effect on HEK-293 (normal cell line) cells, and the cellular uptake level of MNNPs by the HT-29 cell line was enhanced compared to the control group. In conclusion, silibinin-loaded MNNPs complex can be considered as an efficient treatment approach for colorectal cancer cells.

Keywords: colon cancer; drug delivery; magnetic nanoparticle; niosome; silibinin; targeted therapy.

Grants and funding

This study is a part of an MSc thesis (Grant no: 68129) and the authors acknowledge the financial support provided by the Research Vice-Chancellor of Tabriz University of Medical Sciences.